Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection

Tropical Medicine and International Health

Volumn 12, Issue 6, 2007, Pages 700-708

  Shamputa, Isdore Chola ^a,b   Deun, Armand Van ^a   Salim, Md Abdul Hamid ^c   Hossain, Md Anwar ^c   Fissette, Krista ^a   Rijk, Pim De ^a   Rigouts, Leen ^a   Portaels, Françoise ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

^c Damien Foundation Bangladesh   (Bangladesh)

Author keywords

DNA fingerprinting; Reactivation; Reinfection; Treatment failure; Tuberculosis

Indexed keywords

BACTERIAL DNA; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; THIOACETAZONE;

BACTERIUM; DISEASE INCIDENCE; DISEASE PREVALENCE; DISEASE TREATMENT; DNA FINGERPRINTING; HUMAN IMMUNODEFICIENCY VIRUS; PUBLIC HEALTH; RURAL POPULATION; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA FINGERPRINTING; DNA ISOLATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; RECURRENT INFECTION; REINFECTION; RURAL POPULATION; SPUTUM SMEAR; SUPERINFECTION; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BANGLADESH; DNA FINGERPRINTING; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECURRENCE; RURAL HEALTH; TANDEM REPEAT SEQUENCES; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

MYCOBACTERIUM TUBERCULOSIS;

EID: 34249911466     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2007.01840.x     Document Type: Article

References (38)

1. Bandera A, Gori A, Catozzi L et al. (2001) Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. Journal of Clinical Microbiology 39, 2213 2218.
2. Caminero JA, Pena MJ, Campos-Herrero MI et al. (2001) Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. American Journal of Respiratory Critical Care Medicine 163, 717 720.
3. Canetti G, Fox W, Khomenko A et al. (1969) Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programs. Bulletin of the World Health Organization 41, 21 43.
4. Chaves F, Dronda F, Alonso-Sanz M Noriega AR (1999) Evidence of exogenous reinfection and mixed infection with more than one strain of Mycobacterium tuberculosis among Spanish HIV-infected inmates. AIDS 13, 615 620.
5. Das S, Paramasivan CN, Lowrie DB, Prabhakar R Narayanan PR (1995) IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, south India. Tubercle & Lung Disease 76, 550 554.
6. De Boer AS, Kremer K, Borgdorff MW et al. (2000) Genetic heterogeneity in Mycobacterium tuberculosis isolates reflected in IS6110 restriction fragment length polymorphism patterns as low-intensity bands. Journal of Clinical Microbiology 38, 4478 4484.
7. Fitzpatrick L, Braden C, Cronin W et al. (2004) Investigation of Laboratory cross-contamination of Mycobacterium tuberculosis cultures. Clinical Infectious Diseases 38, e52 54.
8. Frothingham R Meeker-O'Connell WA (1998) Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats. Microbiology 144, 1189 1196.
9. Garcia de Viedma D, Marin M, Hernangomez S et al. (2002) Tuberculosis recurrences: reinfection plays a role in a population whose clinical/ epidemiological characteristics do not favor reinfection. Archives of Internal Medicine 162, 1873 1879.
10. Glynn JR, Yates MD, Crampin AC et al. (2004) DNA fingerprint changes in tuberculosis: reinfection, evolution, or laboratory error Journal of Infectious Diseases 190, 1158 1166.
11. Johnson JL, Okwera A, Nsubuga P et al. (2000) Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. International Journal of Tuberculosis and Lung Disease 4, 1032 1040.
12. Kamerbeek J, Schouls L, Kolk A et al. (1997) Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. Journal of Clinical Microbiology 35, 907 914.
13. Katz HL (1958) Reactivations of tuberculous disease in 250 consecutive surgical resections in 248 cases followed from one to six years. In : Veterans Administration-Armed Forces, National Tuberculosis Association. Transactions of the 17th Conference on the Chemotherapy of Tuberculosis. Government Printing Office, Washington, DC, pp. 214 217.
14. Kruuner A, Pehme L, Ghebremichael S, Koivula T, Hoffner SE Mikelsaar M (2002) Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis. Clinical Infectious Diseases 35, 146 155.
15. Laszlo A, Rahman M, Espinal M, Raviglione M WHO/IUTLD Network of supranational reference laboratories (2002) Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. International Journal of Tuberculosis and Lung Disease 6, 748 756.
16. March F, Garriga X, Rodriguez P et al. (1997) Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clinical Infectious Diseases 25, 1044 1104.
17. Mazars E, Lesjean S, Banuls AL et al. (2001) High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. Proceedings of the National Academy of Science 98, 1901 1906.
18. Mukherjee JS, Rich ML, Socci AR et al. (2004) Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363, 474 481.
19. Murray J, Sonnenberg P, Shearer SC Godfrey-Faussett P (1999) Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. American Journal Respiratory and Critical Care 159, 733 737.
20. Nardell E, McInnis B, Thomas B Weidhaas S (1986) Exogenous reinfection with tuberculosis in a shelter for the homeless. New England Journal of Medicine 315, 1570 1575.
21. Portaels F, Rigouts L, Shamputa IC, Van Deun A Aziz MA (2006) Tuberculosis drug resistance in the world. In : Reichman and Hershfield's Tuberculosis: A comprehensive International Approach, 3rd Edn, Part B (ed. M Raviglione) Informa Healthcare. New York, pp. 823 849.
22. Salim AH, Gees W Kibra W (2001) Annual Activities Report. Damien Foundation, Bangladesh.
23. Shamputa IC, Rigouts L, Eyongeta LA et al. (2004) Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. Journal of Clinical Microbiology 42, 5528 5536.
24. Shamputa IC, Jugheli L, Sadradze N et al. (2006) Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respiratory Research 7, 99.
25. Small PM, Shafer RW, Hopewell PC et al. (1993) Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. New England Journal of Medicine 328, 1137 1144.
26. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B Godfrey-Faussett P (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358, 1687 1693.
27. Strassle A, Putnik J, Weber R, Fehr-Merhof A, Wust J Pfyffer GE (1997) Molecular epidemiology of Mycobacterium tuberculosis strains isolated from patients in a human immunodeficiency virus cohort in Switzerland. Journal of Clinical Microbiology 35, 374 378.
28. Telenti A, Honore N, Bernasconi C et al. (1997) Genotypic assessment of INH and RIF resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. Journal of Clinical Microbiology 35, 719 723.
29. Theisen A, Reichel C, Rusch-Gerdes S et al. (1995) Mixed-strain infection with a drug-sensitive and multidrug-resistant strain of Mycobacterium tuberculosis. Lancet 345, 1512.
30. Van Deun A, Aung KJM, Chowdhury S et al. (1999) Drug susceptibility of Mycobacterium tuberculosis in a rural area of Bangladesh and its relevance to the national treatment regimens. International Journal of Tuberculosis and Lung Disease 3, 143 148.
31. Van Deun A, Salim AH, Rigouts L, Rahman M, Fissette K Portaels F (2001) Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. International Journal of Tuberculosis and Lung Disease 5, 329 338.
32. Van Deun A, Salim AH, Daru P et al. (2004) Drug resistance monitoring: combined rates may be the best indicator of programme performance. International Journal of Tuberculosis and Lung Disease 8, 23 30.
33. Van Embden JD, Cave MD, Crawford JT et al. (1993) Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. Journal of Clinical Microbiology 31, 406 409.
34. Van Rie A, Warren RM, Beyers N et al. (1999a) Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling ''strain W'' among noninstitutionalized, human immunodeficiency virus-seronegative patients. Journal of Infectious Diseases 180, 1608 1615.
35. Van Rie A, Warren R, Richardson M et al. (1999b) Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. New England Journal of Medicine 341, 1174 1179.
36. Verver S, Warren RM, Beyers N et al. (2005) Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. American Journal of Respiratory and Critical Care Medicine 171, 1430 1435.
37. World Health Organization (1997) Treatment of Tuberculosis: Guidelines for National Programmes. World Health Organisation, Geneva, Switzerland.
38. World Health Organization (2004) The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance; 1999-2002.